Project Grant R56HL163583
Award Date 9/23/23
Completion Date 8/31/24
Dollars Obligated $715K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Indiana University Indianapolis a $249,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion scheduled for June 30, 2028. This award supports Dr. James's career development and establishment of an independent research group investigating aminopeptidase N (APN)-driven signaling and mitochondrial dysfunction in pulmonary...
- Federal Grant Award Summary Award Overview Indiana University Indianapolis received a $169,444 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, through August 31, 2030. This award supports the development and pilot testing of a stress management intervention specifically designed for Black adults with hypertension, a population that experiences disproportionate cardiovascular...
- Federal Project Grant Award Summary The University of Illinois received a $522,794 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2025, with completion targeted for March 31, 2029. This award funds research investigating the role of the voltage-gated proton channel HV1 in pulmonary hypertension pathogenesis. The research will employ transgenic mouse models and complementary in vivo...
- This $596,401 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on a novel long non-coding RNA termed MCRL1 and its role in regulating human cardiac and hematopoietic differentiation. The project will be conducted by researchers at Indiana University Indianapolis, with a sub-award to Northwestern University. The key focus is investigating how MCRL1 interacts with the beta-catenin signaling pathway to modulate...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $491,056.01 to The Research Foundation For The State University Of New York (SUNY at Binghamton) on May 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The project, titled "Vascular Smooth Muscle VPS34 in Pulmonary Arterial Hypertension," will be completed by April 30, 2028, and is conducted at the Binghamton, New York facility. The grant funds research aimed at...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received an $800,962 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with performance from September 15, 2025, through June 30, 2030. The award supports research investigating the molecular mechanisms underlying endothelial inflammation, C-terminal Src kinase (CSK) dysregulation, and fibrosis in early pulmonary arterial hypertension...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $414,996.00 to Indiana University Indianapolis under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms of junctional proteins in post-surgical lymphedema. The research, which commenced August 15, 2025, and is scheduled for completion by May 31, 2030, addresses a significant clinical problem affecting an estimated 5-10 million Americans....
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $487,567 to Indiana University to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects (CHDs). The research aims to identify genetic variants and biological pathways associated with CHDs, as well as build predictive models leveraging genetic, epigenetic,...
- This federal Project Grant award, totaling $786,060.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to investigate the role of hypertension-induced trained immunity in myeloid cells as a determinant of atherosclerosis. The primary awardee, Vanderbilt University Medical Center, is conducting this research to explore how hypertension can lead to long-lasting changes in the immune system that promote chronic...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $319,248 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of August 1, 2025 and completion date of July 31, 2030. The research project, titled "Hypoxia-Inducible Factor (HIF)-Driven Modulation of Alveolar Regeneration," focuses on developing novel therapeutic approaches to address idiopathic...